博拓生物(688767) - 2021 Q3 - 季度财报

Financial Performance - The company's revenue for Q3 2021 reached CNY 345,463,545.50, representing a year-over-year increase of 129.79%[5] - Net profit attributable to shareholders for Q3 2021 was CNY 150,379,747.43, reflecting a significant increase of 179.93% compared to the same period last year[5] - The basic earnings per share for Q3 2021 was CNY 1.88, which is an increase of 180.60% year-over-year[6] - The company reported a net profit attributable to shareholders of CNY 719,110,208.38 for the year-to-date period, which is an increase of 101.88% compared to the same period last year[5] - The diluted earnings per share for the year-to-date period was CNY 8.99, reflecting a growth of 102.02% year-over-year[10] - Net profit for the first three quarters of 2021 was ¥719,656,667.86, up from ¥356,492,232.96 in 2020, reflecting a growth of approximately 102%[22] - Basic earnings per share for the first three quarters of 2021 were ¥8.99, compared to ¥4.45 in the same period of 2020, marking an increase of about 102%[23] Assets and Liabilities - Total assets as of the end of Q3 2021 amounted to CNY 2,315,898,293.32, showing a growth of 265.33% compared to the previous year[10] - Total current assets rose to ¥1,979,624,065.65, up from ¥467,986,371.62 in the previous year[16] - Non-current assets increased to ¥336,274,227.67 from ¥165,929,524.10 year-over-year[17] - Total liabilities as of the end of the reporting period amounted to ¥323,919,751.75, compared to ¥190,892,214.33 in the previous year, showing an increase of about 70%[18] - The total liabilities increased from ¥190,892,214.33 to ¥200,154,100.25, indicating a rise in the company's obligations[31] Cash Flow - The net cash flow from operating activities for the year-to-date period was CNY 795,973,298.39, an increase of 124.54%[6] - The net cash flow from operating activities for Q3 2021 was ¥795,973,298.39, an increase from ¥354,486,898.74 in Q3 2020, representing a growth of approximately 124.8%[26] - Cash generated from operating activities in the first three quarters of 2021 was ¥1,474,750,036.81, compared to ¥651,883,260.39 in 2020, representing an increase of approximately 126%[25] - The net cash flow from financing activities after outflows was ¥829,810,921.57, a turnaround from a negative cash flow of -¥128,308,228.05 in the previous year[27] - The company received tax refunds amounting to ¥56,373,677.54, compared to ¥17,782,412.91 in the previous year, showing an increase of approximately 216.5%[26] Shareholder Information - Total number of common shareholders at the end of the reporting period is 14,484[13] - The largest shareholder, Hangzhou Tuokang Investment Co., Ltd., holds 24,896,000 shares, accounting for 23.34% of total shares[13] - The company has no pledged, marked, or frozen shares among its top shareholders[13] Research and Development - Research and development expenses for Q3 2021 totaled CNY 11,375,236.55, accounting for 3.29% of revenue, a decrease of 2.04 percentage points from the previous year[6] - The company has invested ¥38,479,049.32 in research and development expenses during the first three quarters of 2021, compared to ¥26,395,079.08 in the same period of 2020, reflecting an increase of approximately 46%[21] Operational Highlights - The company experienced a significant increase in sales revenue and profit scale due to the heightened demand for COVID-19 testing products[9] - Total operating revenue for the first three quarters of 2021 reached ¥1,503,248,673.80, a significant increase from ¥643,793,253.72 in the same period of 2020, representing a growth of approximately 133%[21] - Total operating costs for the first three quarters of 2021 were ¥661,835,705.18, compared to ¥221,032,229.89 in 2020, indicating an increase of about 199%[21] Other Financial Metrics - The company reported a decrease in other comprehensive income, with a net amount of -¥71,027.99 for the first three quarters of 2021, compared to ¥205,116.11 in 2020[22] - The company has not disclosed any significant new strategies or product developments during the reporting period[15]